SI1740204T1 - Medicinska uporaba alfa-manozidaze - Google Patents
Medicinska uporaba alfa-manozidaze Download PDFInfo
- Publication number
- SI1740204T1 SI1740204T1 SI200532209T SI200532209T SI1740204T1 SI 1740204 T1 SI1740204 T1 SI 1740204T1 SI 200532209 T SI200532209 T SI 200532209T SI 200532209 T SI200532209 T SI 200532209T SI 1740204 T1 SI1740204 T1 SI 1740204T1
- Authority
- SI
- Slovenia
- Prior art keywords
- alpha
- use according
- medicament
- lysosomal alpha
- manosidase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01024—Alpha-mannosidase (3.2.1.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
- MEDICINSKA UPORABA ALFA-MANOZIDAZE PATENTNI ZAHTEVKI1. Uporaba lizosomske alfa-manozidaze za pripravo zdravila za zdravljenje alfa-manozidoze, pri čemer je navedeno zdravilo treba dajati z intravenoznim dajanjem.
- 2. Uporaba po zahtevku 1, kjer je zdravilo treba dajati z infuzijo ali ponovljeno intravensko injiciranje s frekvenco, ki ustreza 1 do 5 dnevnih vbrizgavanj, 1 do 5 injiciranj na teden, 1 do 5 injiciranj vsakih 2 tedna ali 1 do 5 injiciranj vsak mesec.
- 3. Uporaba po zahtevku 1 ali zahtevku 2, kjer navedeno zdravilo ne obsega komponente z znano sposobnostjo za tarčne celice znotraj osrednjega živčnega sistema.
- 4. Uporaba po katerem koli od zahtevkov 1-3, kjer lizosomska alfa-manozidaza obsega aminokislinsko sekvenco SEQ ID NO: 1.
- 5. Uporaba po katerem koli od zahtevkov 1-4, kjer je omenjeno zdravilo treba dajati v frekvenci, ki ustreza do 1-5 injiciranj na teden.
- 6. Uporaba po katerem koli od zahtevkov 1-5, kjer omenjeno zdravilo ne obsega komponente za ciljanje celic znotraj osrednjega živčnega sistema in ne obsega komponente, s sposobnostjo delovanja kot vehikel za prehod skozi krvno-možgansko pregrado.
- 7. Uporaba po katerem koli izmed predhodnih zahtevkov, kjer se omenjeno zdravilo daje v količini, ki je v razponu od 5 do 300 mU lizosomske alfa-manozidaze na gram telesne mase subjekta, ki ga je treba zdraviti.
- 8. Uporaba po katerem koli izmed predhodnih zahtevkov, kjer se omenjeno zdravilo daje v količini, ki je v razponu od 20 do 100 mU lizosomske alfa-manozidaze na gram telesne mase subjekta, ki ga je treba zdraviti.
- 9. Uporaba po katerem koli od prejšnjih zahtevkov, kjer frakcija omenjene lizosomske alfa-manozidaze sestoji iz lizosomske alfa-manozidaze, ki ima eno ali več N-vezanih oligosaharidov, ki nosijo manoza 6-fosfat ostanke.
- 10. Uporaba po katerem koli od predhodnih zahtevkov, kjer frakcija, ki ustreza od 1 do 75% aktivnosti pripravka lizosomske alfa-manozidaze, ki se veže na manoza-6-fosfat-receptor.
- 11. Uporaba po zahtevku 10, kjer navedena frakcija ustreza od 10 do 50% aktivnosti pripravka lizosomske alfa-manozidaze.
- 12. Uporaba po zahtevku 10, pri čemer navedena frakcija ustreza od 20 do 40% aktivnosti pripravka lizosomske alfa-manozidaze.
- 13. Uporaba po katerem koli izmed predhodnih zahtevkov, kjer je omenjena lizosomska alfa-manozidaza rekombinantni encim.
- 14. Uporaba po katerem koli od predhodnih zahtevkov, kjer je navedena lizosomska alfa-manozidaza proizvedena v celičnem sistemu sesalca.
- 15. Uporaba po zahtevku 14, kjer je omenjenicelični sistem sesalcev celična linija CHO.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55810804P | 2004-04-01 | 2004-04-01 | |
| DKPA200400528 | 2004-04-01 | ||
| PCT/DK2005/000228 WO2005094874A1 (en) | 2004-04-01 | 2005-04-01 | Medical use of alpha-mannosidase |
| EP05715146.6A EP1740204B1 (en) | 2004-04-01 | 2005-04-01 | Medicinal use of alpha-mannosidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1740204T1 true SI1740204T1 (sl) | 2018-07-31 |
Family
ID=34962870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200532209T SI1740204T1 (sl) | 2004-04-01 | 2005-04-01 | Medicinska uporaba alfa-manozidaze |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1740204B1 (sl) |
| DK (1) | DK1740204T3 (sl) |
| PL (1) | PL1740204T3 (sl) |
| SI (1) | SI1740204T1 (sl) |
| WO (1) | WO2005094874A1 (sl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| AU2005209360B2 (en) | 2004-01-30 | 2009-06-25 | Takeda Pharmaceutical Company Limited | Production and purification of recombinant arylsulfatase A |
| BRPI0620155B1 (pt) * | 2005-12-15 | 2015-07-21 | Lilly Co Eli | Composição adequada para administração oral a um animal compreendendo uma enzima redutora de estresse imunológico em um veículo aceitável por via oral |
| SI2628746T1 (sl) | 2006-04-04 | 2019-04-30 | Chiesi Farmaceutici S.P.A. | Proces za koncentriranje polipeptida |
| LT2457920T (lt) | 2007-01-18 | 2018-02-12 | Genzyme Corporation | Oligosacharidai, apimantys aminooksigrupę, ir jų konjugatai |
| WO2008089339A2 (en) * | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
| CA2747230C (en) | 2008-12-16 | 2019-06-11 | Genzyme Corporation | Oligosaccharide-protein conjugates |
| SI3281636T1 (sl) * | 2010-02-24 | 2020-11-30 | Chiesi Farmaceutici S.P.A. | Postopek proizvodnje in čiščenja rekombinantne lizosomske alfa-manozidaze |
| WO2013009686A2 (en) | 2011-07-08 | 2013-01-17 | Shire Human Genetic Therapies, Inc. | Methods for purification of arylsulfatase a |
| MX2015008875A (es) | 2013-01-09 | 2015-10-22 | Shire Human Genetic Therapies | Metodos para la purificacion de arilsulfatasa a. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5295500A (en) * | 1999-05-28 | 2000-12-18 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
| WO2002099092A2 (en) * | 2001-06-07 | 2002-12-12 | Hemebiotech A/S | Production of recombinant human lysosomal alpha-mannosidase |
-
2005
- 2005-04-01 PL PL05715146T patent/PL1740204T3/pl unknown
- 2005-04-01 WO PCT/DK2005/000228 patent/WO2005094874A1/en active Application Filing
- 2005-04-01 EP EP05715146.6A patent/EP1740204B1/en active Active
- 2005-04-01 SI SI200532209T patent/SI1740204T1/sl unknown
- 2005-04-01 DK DK05715146.6T patent/DK1740204T3/en active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1740204B1 (en) | 2018-03-14 |
| PL1740204T3 (pl) | 2018-08-31 |
| EP1740204A1 (en) | 2007-01-10 |
| WO2005094874A1 (en) | 2005-10-13 |
| DK1740204T3 (en) | 2018-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1740204T1 (sl) | Medicinska uporaba alfa-manozidaze | |
| US11826405B2 (en) | Neurotoxin compositions for use in treating headache | |
| KR102455814B1 (ko) | 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제 | |
| EP1390493B1 (en) | Antisense oligonucleotide against human acetylcholinesterase isoform r (ache-r) and uses thereof | |
| SI2379104T1 (sl) | Pripravki Toksina Botulina Za Injiciranje | |
| JP2013538788A5 (sl) | ||
| HRP20150438T1 (hr) | Uporaba lizosomalne kiselinske lipaze za lijeäśenje deficijencije lizosomalne kiselinske lipaze kod pacijenata | |
| US20230105611A1 (en) | Combination therapy with cgrp antagonists and clostridial derivatives | |
| Carroll et al. | Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats | |
| EP3700525A1 (en) | Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stress | |
| Osenbach et al. | Neuraxial infusion in patients with chronic intractable cancer and noncancer pain | |
| CN100431547C (zh) | 一种关节腔内注射治疗骨关节炎的雷公藤内酯醇复方制剂 | |
| AU2007247321A1 (en) | GlutaDON | |
| Fisher et al. | New routes for delivery of anti-epileptic medications | |
| US9555070B2 (en) | Pan-antiviral peptides for protein kinase inhibition | |
| CN102988282A (zh) | 一种改善断奶仔猪肠道发育的针剂溶液的配制方法 | |
| US20210130445A1 (en) | CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders | |
| US7807635B1 (en) | Pan-antiviral peptides for protein kinase inhibition | |
| Burnham et al. | The effect of taurine on kindled seizures in the rat | |
| Prieto et al. | Acute Intermittent Porphyria: Novel Etiologic and Pathogenic Therapies Based on RNA Transfer to the Liver | |
| Sano et al. | Steroids and the blood-brain barrier with special reference to astrocytic cells | |
| US20110124718A1 (en) | Reduction Of Acetaminophen Toxicity By Dietary Milk Thistle Extract | |
| Bateman et al. | KANCHANOMYCIN (NSC-62773): A PHASE I STUDY2, 3 | |
| RU2022129038A (ru) | Способы и композиции для доставки в цнс арилсульфатазы а | |
| CN114828962A (zh) | 用于治疗cns淋巴瘤的谷卡匹酶与甲氨蝶呤/利妥昔单抗的联合疗法 |